Medical Director, Early Clinical Development (Cell Therapy)

More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotechnology company redefining the transplant process by developing next-generation cell therapies with the goal of providing significantly better survival rates with dramatically fewer risks. With our purified, high-precision investigational cell therapies we hope to not only replace patients' blood and immune systems with healthy ones, but also restore their lives.

Unique opportunity! We are seeking a Medical Director to serve as medical lead for our next-generation cell therapy program (Orca-Q), in non-malignant diseases, including planned trials in autoimmune indications. This role is critical in conceptualizing multiple Phase 1 studies, developing the associated protocols, analyzing data, and conducting the clinical trial. The candidate must work collaboratively within Orca Bio and also with primary investigators (PIs) nationwide to progress the program towards product registration.